MAY 11, 2017 06:30 AM PDT

Towards Personalized Therapy for Prostate Cancer

WRITTEN BY: Xuan Pham

Men with prostate cancer need not waste precious time on drugs that may not work out for them. In studying the treatment response of hundreds of men receiving treatment for prostate cancer, researchers from the Institute of Cancer Research, London, say they’ve developed a blood test that can predict who will benefit from certain cancer treatments.

Image credit: pixabay.com

Prostate cancer represents a huge health risk – it is the most common form of cancer in men. In 2013, nearly 2.8 million men were living with prostate cancer in the US. While prostate cancer has one of the better 5-year survival rates, not all patients respond to treatment with success. In particular, two drugs, abiraterone and enzalutamide, have mixed responses.

"Abiraterone and enzalutamide are excellent treatments for advanced prostate cancer and some men can take these drugs for years without seeing a return of their cancer. But in other men, these drugs do not work well and the disease rapidly returns. Currently there is no approved test to help doctors choose whether these are the best treatments for an individual,” said Dr. Gerhardt Attard, the senior investigator of the study from the Institute of Cancer Research.

Attard’s team analyzed blood samples from men who were receiving abiraterone or enzalutamide. They collected samples from before treatment, and after disease progression.

They found that men with multiple copies of the androgen receptor gene were less likely to respond to the drug, and consequently, were four times more likely to succumb from the disease.

"We have developed a robust test that can be used in the clinic to pick out which men with advanced prostate cancer are likely to respond to abiraterone and enzalutamide, and which men might need alternative treatments,” said Dr. Attard.

The team estimate their test will be quite inexpensive but tremendously useful in tailoring treatment to individual patients. "Our method costs less than £50, is quick to provide results, and can be implemented in hospital laboratories across the NHS. We are now looking to assess our test in prospective clinical trials and would hope it can become part of standard patient care,” said Dr. Attard.

"A man with incurable prostate cancer does not have time to waste taking drugs that will not work for him. To stop prostate cancer from being a killer, we need to move away from a one-size-fits-all approach to treatment. This test could be a significant step towards that and we'll be watching its development very closely. Thanks to our supporters, we are ramping up investment in prostate cancer research to get the right drug for the right man at the right time,” said Dr. Iain Frame, the Director of Research at Prostate Cancer UK.

The test still has be validated in clinical trials. “If further studies confirm this test is reliable, it could also help doctors choose better options for men whose prostate cancer is unlikely to respond to standard treatments,” said Dr. Emma Smith, science information manager at Cancer Research UK.

Additional source: Institute of Cancer Research

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 18, 2019
Cancer
OCT 18, 2019
More younger people diagnosed with colorectal cancer
According to the American Cancer Society (ACS), colorectal cancer is the third most commonly diagnosed cancer, not including skin cancers. Now new research...
OCT 18, 2019
Immunology
OCT 18, 2019
Are Bacteria Fighting Cancer For Us?
Scientists at the Sanford Burnham Prebys Medical Discovery Institute found that the RNF5 enzyme, produced by a gene in gut microbes affects tumor growth.&n...
OCT 18, 2019
Health & Medicine
OCT 18, 2019
Textured Breast Implants Linked to Rare Cancer Recalled
Yesterday, the U.S. Food and Drug Administration announced the recall of textured breast implants linked to breast implant-associated anaplastic large cell...
OCT 18, 2019
Cancer
OCT 18, 2019
Urine test detects cancer: watch out for blue pee!
New research from MIT engineers and Imperial and published in Nature Nanotechnology could change the way to detect cancer. The study highlights the develop...
OCT 18, 2019
Genetics & Genomics
OCT 18, 2019
A Cancer-Promoting Mutation is Found in 'Junk' DNA
A huge amount of our genome does not code for protein, but it can impact physiology in other ways....
OCT 18, 2019
Cancer
OCT 18, 2019
Looking to the depths of the human genome to understand cancer
Have you ever heard of dark matter? No, I’m not talking about the dark matter of the universe – I mean the dark matter that lives within your g...
Loading Comments...